

RESULTS OF ANNUAL GENERAL MEETING

Paris, France and Cambridge, UK – 29 September 2020– Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, held today its Ordinary and Extraordinary General Meeting

The results of the AGM are set out in the table below, with the Company pleased to announce that all resolutions proposed to the shareholders were duly passed:

Resolutions	Votes For		Votes Against		Result
	Number	%	Number	%	
1) Approval of the parent company financial statements for the year ended 31 December 2019	18,222,352	99.7890	38,532	0.2110	Adopted
2) Approval of the consolidated financial statements for the year ended 31 December 2019	18,222,352	99.7890	38,532	0.2110	Adopted
3) Appropriation of the result for the year ended 31 December 2019	18,114,759	99.4131	106,940	0.5869	Adopted
4) Review of the agreements referred to in Articles L. 225-38 <i>et seq.</i> of the French Commercial Code	18,163,387	99.7494	45,638	0.2506	Adopted
5) Discharge to the Board of Directors	18,161,873	99.5460	82,827	0.4540	Adopted
6) Authorisation for the Company to buy back its own shares	18,136,247	99.2048	145,379	0.7952	Adopted
7) Terms of office of the members of the Board of Directors	18,049,375	98.7764	223,580	1.2236	Adopted
8) Terms of office of the Statutory Auditors	18,212,985	99.7328	48,802	0.2672	Adopted
9) Amount of remuneration allocated to members of the Board of Directors for the year ended 31 December 2019	17,821,689	98.1853	329,384	1.8147	Adopted
10) Amount of remuneration to be allocated to members of the Board of Directors from 1 January 2020	17,692,884	97.4987	453,914	2.5013	Adopted
11) Powers for formalities	18,201,594	99.7658	42,721	0.2342	Adopted

Resolutions	Votes For		Votes Against		Result
	Number	%	Number	%	
12)Amendment of Article 19 of the Company's Articles of Association	18,139,274	99.3793	113,300	0.6207	Adopted
13)Delegation of authority granted to the Board of Directors for the purpose of allocating free shares, existing or new, for the benefit of employees of the Company and of related companies and corporate officers	16,534,574	90.8993	1,655,423	9.1007	Adopted
14)Delegation of authority granted to the Board of Directors for the purpose of granting options to subscribe for and/or purchase shares of the Company, to corporate officers and employees of the Company or of companies in the group, involving the waiver by shareholders of their preferential subscription right to shares issued following the exercise of subscription options	16,178,893	88.7433	2,052,219	11.2567	Adopted
15)Overall limit on delegations relating to free shares and subscription or purchase options	16,658,088	91.4780	1,551,848	8.5220	Adopted
16)Delegation of authority to the Board of Directors for the purpose of issuing ordinary shares of the Company and/or transferable securities giving access to the share capital of the Company, with cancellation of shareholders' preferential subscription rights in favour of specific categories of persons	15,210,240	83.4688	3,012,420	16.5312	Adopted
17)Delegation of authority granted to the Board of Directors for the purpose of increasing the share capital by issuing ordinary shares or securities giving access to ordinary shares to be issued by the Company immediately or in the future in consideration for contributions in kind within the limit of 10% of the share capital, except in the case of a public	16,186,881	88.9385	2,013,199	11.0615	Adopted

Resolutions	Votes For		Votes Against		Result
	Number	%	Number	%	
exchange offer initiated by the Company					
18) Delegation of authority to the Board of Directors for the purpose of issuing ordinary shares and/or transferable securities giving immediate and/or deferred access to the capital of the Company, with cancellation of shareholders' preferential subscription rights and public offerings	15,263,457	83.8253	2,945,202	16.1747	Adopted
19) Delegation of authority to the Board of Directors for the purpose of issuing ordinary shares of the Company and/or transferable securities giving access to the share capital of the Company, with preferential subscription rights	16,683,635	91.5149	1,546,883	8.4851	Adopted
20) Authorisation to the Board of Directors, in the event of a capital increase, with or without shareholders' preferential subscription rights, to increase the number of securities to be issued	15,594,811	85.6974	2,602,713	14.3026	Adopted
21) Overall ceiling on delegations of authority	16,793,807	92.3175	1,397,549	7.6825	Adopted
22) Delegation of authority to the Board of Directors for the purpose of issuing ordinary shares and/or securities giving access to the Company's capital for the benefit of members of a company savings plan	16,086,360	88.7152	2,046,221	11.2848	Adopted
23) Powers for formalities	18,177,470	99.7026	54,219	0.2974	Adopted

Number of participating shareholders (by voting form, proxy or present): 2,326 shareholders representing 18,345,785 shares.

- End -

Contacts

Novacyt SA

Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1276 600081

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black
+44 (0)20 7260 1000

FTI Consulting (International)

Victoria Foster Mitchell / Mary Whittow
+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com / mary.whittow@fticonsulting.com

FTI Consulting (France)

Arnaud de Cheffontaines
+33 (0)147 03 69 48

arnaud.decheffontaines@fticonsulting.com

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of *in vitro* and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information please refer to the website: www.novacyt.com